Form 4: 4D Molecular Therapeutics Chief Legal Officer Exercises and Sells Stock Options

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On June 17, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire 500 shares at $6.49 and 1,250 shares at $8.04.
• He then sold 1,750 shares of common stock at a weighted average price of $23.7106, with individual sales ranging from $23.45 to $24.44.
• These transactions were executed under a 10b5-1 trading plan adopted on October 10, 2023.
• Following these transactions, Bizily directly owns 1,737 shares of common stock and holds options to purchase 49,879 additional shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock transactions by an executive under a pre-arranged trading plan.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like 10b5-1, to manage personal finances.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the existence of a 10b5-1 plan suggests it's part of a pre-determined strategy.

Key Dates